ORGO
Price
$5.00
Change
-$0.02 (-0.40%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
638.09M
61 days until earnings call
PRGO
Price
$22.66
Change
-$0.63 (-2.71%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
3.2B
61 days until earnings call
Interact to see
Advertisement

ORGO vs PRGO

Header iconORGO vs PRGO Comparison
Open Charts ORGO vs PRGOBanner chart's image
Organogenesis Holdings
Price$5.00
Change-$0.02 (-0.40%)
Volume$8.29K
Capitalization638.09M
Perrigo
Price$22.66
Change-$0.63 (-2.71%)
Volume$24.29K
Capitalization3.2B
ORGO vs PRGO Comparison Chart in %
Loading...
ORGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ORGO vs. PRGO commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORGO is a Buy and PRGO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ORGO: $5.03 vs. PRGO: $23.29)
Brand notoriety: ORGO and PRGO are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ORGO: 156% vs. PRGO: 102%
Market capitalization -- ORGO: $638.09M vs. PRGO: $3.2B
ORGO [@Pharmaceuticals: Generic] is valued at $638.09M. PRGO’s [@Pharmaceuticals: Generic] market capitalization is $3.2B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.9B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORGO’s FA Score shows that 1 FA rating(s) are green whilePRGO’s FA Score has 2 green FA rating(s).

  • ORGO’s FA Score: 1 green, 4 red.
  • PRGO’s FA Score: 2 green, 3 red.
According to our system of comparison, both ORGO and PRGO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORGO’s TA Score shows that 5 TA indicator(s) are bullish while PRGO’s TA Score has 6 bullish TA indicator(s).

  • ORGO’s TA Score: 5 bullish, 3 bearish.
  • PRGO’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, ORGO is a better buy in the short-term than PRGO.

Price Growth

ORGO (@Pharmaceuticals: Generic) experienced а -1.76% price change this week, while PRGO (@Pharmaceuticals: Generic) price change was -0.77% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.80%. For the same industry, the average monthly price growth was +10.12%, and the average quarterly price growth was +85.54%.

Reported Earning Dates

ORGO is expected to report earnings on Nov 05, 2025.

PRGO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.80% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRGO($3.2B) has a higher market cap than ORGO($638M). PRGO has higher P/E ratio than ORGO: PRGO (2827.00) vs ORGO (63.75). ORGO YTD gains are higher at: 57.188 vs. PRGO (-6.356). ORGO has less debt than PRGO: ORGO (40.8M) vs PRGO (3.65B).
ORGOPRGOORGO / PRGO
Capitalization638M3.2B20%
EBITDA3.19MN/A-
Gain YTD57.188-6.356-900%
P/E Ratio63.752827.002%
Revenue429MN/A-
Total Cash73.1MN/A-
Total Debt40.8M3.65B1%
FUNDAMENTALS RATINGS
ORGO vs PRGO: Fundamental Ratings
ORGO
PRGO
OUTLOOK RATING
1..100
2153
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
33
Fair valued
PROFIT vs RISK RATING
1..100
93100
SMR RATING
1..100
9592
PRICE GROWTH RATING
1..100
3982
P/E GROWTH RATING
1..100
112
SEASONALITY SCORE
1..100
90n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRGO's Valuation (33) in the Pharmaceuticals Other industry is somewhat better than the same rating for ORGO (75) in the Financial Conglomerates industry. This means that PRGO’s stock grew somewhat faster than ORGO’s over the last 12 months.

ORGO's Profit vs Risk Rating (93) in the Financial Conglomerates industry is in the same range as PRGO (100) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to PRGO’s over the last 12 months.

PRGO's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as ORGO (95) in the Financial Conglomerates industry. This means that PRGO’s stock grew similarly to ORGO’s over the last 12 months.

ORGO's Price Growth Rating (39) in the Financial Conglomerates industry is somewhat better than the same rating for PRGO (82) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew somewhat faster than PRGO’s over the last 12 months.

PRGO's P/E Growth Rating (2) in the Pharmaceuticals Other industry is in the same range as ORGO (11) in the Financial Conglomerates industry. This means that PRGO’s stock grew similarly to ORGO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORGOPRGO
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
65%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
72%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
60%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
66%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 17 days ago
61%
Declines
ODDS (%)
Bearish Trend 18 days ago
87%
Bearish Trend 2 days ago
65%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
65%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 4 days ago
53%
View a ticker or compare two or three
Interact to see
Advertisement
ORGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TAAEX45.470.44
+0.98%
Transamerica Capital Growth R
HLRRX9.860.09
+0.92%
LDR Real Estate Value Opportunity Instl
MVALX42.740.33
+0.78%
Meridian Contrarian Legacy
ARIIX10.810.06
+0.56%
AB Global Real Estate Investment II I
JEPIX14.130.04
+0.28%
JPMorgan Equity Premium Income I

ORGO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORGO has been loosely correlated with ANIP. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ORGO jumps, then ANIP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORGO
1D Price
Change %
ORGO100%
+1.41%
ANIP - ORGO
47%
Loosely correlated
+1.14%
PRGO - ORGO
46%
Loosely correlated
-0.17%
ANIK - ORGO
33%
Loosely correlated
+0.89%
AMRX - ORGO
29%
Poorly correlated
+0.10%
GTBIF - ORGO
29%
Poorly correlated
-2.94%
More

PRGO and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRGO has been loosely correlated with ORGO. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if PRGO jumps, then ORGO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRGO
1D Price
Change %
PRGO100%
-0.17%
ORGO - PRGO
46%
Loosely correlated
+1.41%
EOLS - PRGO
43%
Loosely correlated
+1.76%
MLLNF - PRGO
43%
Loosely correlated
N/A
AMRX - PRGO
38%
Loosely correlated
+0.10%
ALKS - PRGO
33%
Poorly correlated
-3.60%
More